ARQT Arcutis Biotherapeutics Inc

$27.33

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company is headquartered in Westlake Village, California.

Website: https://www.arcutis.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1787306
Address
2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE, CA, US
Valuation
Market Cap
$1.54B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
9.80
Performance
EPS
$-1.16
Dividend Yield
—
Profit Margin
-71.30%
ROE
-113.80%
Technicals
50D MA
$14.20
200D MA
$11.76
52W High
$17.75
52W Low
$6.99
Fundamentals
Shares Outstanding
119M
Target Price
$21.00
Beta
1.68

ARQT EPS Estimates vs Actual

● Estimated
● Actual

ARQT News & Sentiment

Nov 21, 2025 • Motley Fool BULLISH
Why Shares in Arcutis Biotherapeutics Surged Again This Week
The company continues to receive good news from the Food and Drug Administration.
Nov 20, 2025 • Zacks Commentary SOMEWHAT-BULLISH
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.
Nov 20, 2025 • Zacks Commentary SOMEWHAT-BULLISH
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
Nov 20, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Arcutis Biotherapeutics, Inc. ( ARQT ) Soars to 52-Week High, Time to Cash Out?
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Nov 19, 2025 • Zacks Commentary NEUTRAL
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects
Vanda Pharmaceuticals stock rallies after phase II data show tradipitant sharply cuts Wegovy-related nausea and vomiting in overweight and obese adults.
Nov 18, 2025 • Zacks Commentary NEUTRAL
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know
Ventyx Biosciences stock jumps 156% as its mid-stage obesity and CV risk study achieves key safety, tolerability, anti-inflammatory and CV risk reduction goals.
Sentiment Snapshot

Average Sentiment Score:

0.307
50 articles with scored sentiment

Overall Sentiment:

Bullish

ARQT Reported Earnings

Aug 06, 2025
Jun 30, 2025 (Pre market)
0.04 Surprise
  • Reported EPS: $-0.13
  • Estimate: $-0.17
  • Whisper: —
  • Surprise %: 23.5%
May 06, 2025
Mar 31, 2025 (Post market)
0.53 Surprise
  • Reported EPS: $-0.20
  • Estimate: $-0.73
  • Whisper: —
  • Surprise %: 72.6%
Feb 25, 2025
Dec 31, 2024 (Pre market)
0.17 Surprise
  • Reported EPS: $-0.09
  • Estimate: $-0.26
  • Whisper: —
  • Surprise %: 66.0%
Nov 06, 2024
Sep 30, 2024 (Post market)
0.09 Surprise
  • Reported EPS: $-0.33
  • Estimate: $-0.42
  • Whisper: —
  • Surprise %: 21.4%
Aug 14, 2024
Jun 30, 2024 (Post market)
0.1 Surprise
  • Reported EPS: $-0.42
  • Estimate: $-0.52
  • Whisper: —
  • Surprise %: 19.2%
May 14, 2024
Mar 31, 2024 (Post market)
0.41 Surprise
  • Reported EPS: $-0.32
  • Estimate: $-0.73
  • Whisper: —
  • Surprise %: 56.2%
Feb 27, 2024
Dec 31, 2023 (Pre market)
0.05 Surprise
  • Reported EPS: $-0.72
  • Estimate: $-0.77
  • Whisper: —
  • Surprise %: 6.5%
Nov 03, 2023
Sep 30, 2023 (Pre market)
0.13 Surprise
  • Reported EPS: $-0.73
  • Estimate: $-0.86
  • Whisper: —
  • Surprise %: 15.1%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.09 Surprise
  • Reported EPS: $-1.16
  • Estimate: $-1.25
  • Whisper: —
  • Surprise %: 7.2%

Financials